News | January 25, 2022
Control Print’s 3-ply surgical masks receive USFDA 510(K) authorisation
The company has been manufacturing masks since the Covid-19 outbreak in 2020
The company has been manufacturing masks since the Covid-19 outbreak in 2020
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Previously, the use of the drug was limited to patients requiring hospitalization
Go-ahead for pivotal clinical trial which is expected to commence by March
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
Subscribe To Our Newsletter & Stay Updated
